Cardiovascular disease (ischaemic
|
|
- Brook Ford
- 5 years ago
- Views:
Transcription
1 diabetes the CV Risk equivalent Earn 3 CPD Points online The heart: Where sugar and fat meet KEY MESSAGES Dr Zaheer Bayat Endocrinologist/Physician Mediclinic Sandton Johannesburg Type 2 diabetes mellitus is a medically incurable disease It is often inadequately controlled Cardiovascular problems will almost certainly kill your diabetic patient 1 Not all drugs are equally safe There needs to be a move away from drugs that harm There are gaps in our knowledge that we need to keep working towards addressing The path ahead is exciting indeed. Cardiovascular disease (ischaemic heart disease and stroke) ranks among the top 10 causes of death in all countries worldwide, regardless of whether they re developed or developing countries. Across the world, 33 people die every minute from cardiovascular disease and importantly 75% of diabetic patients will die from a fatal cardiovascular event 1. said Dr Zaheer Bayat. He was speaking at a CPD meeting hosted by the South African Academy of Family Practice on 12 July. The link between diabetes and cardiovascular disease is well established and diabetes is a huge and growing problem. In 2013 worldwide, for every one person with HIV, there were 11 with diabetes and that fails to take into account the hidden data, as many diabetics remain undiagnosed. Sub-Saharan Africa will see a 99% increase in diabetes over the next 20 years, he said. A worldwide epidemic of obesity is driving the rapidly increasing incidence of type 2 diabetes. 2,3 In the USA in 2010, one in three people was overweight ( arrowres.com/program-obesity.html) so this is a massive problem. The more obese someone is, the greater their likelihood of developing diabetes. Diabetes is not a mild disease. It is the leading cause of blindness, non-traumarelated amputations and end-stage renal disease. Diabetic retinopathy is the most frequent cause of new cases of blindness Table 1. Available therapies for Glycaemic control: Pharmacological control Class Biguanides Glitazones Alpha-glucosidase SGLT-2 (sodium glucose transporter) Inhibitor GLP-1 agonists (Glucagon- like peptide-1) DPP-4 inhibitors (Dipeptidyl peptidase-4) Pharmacological action Decrease hepatic glucose production and increase glucose uptake Increase insulin sensitivity and glucose uptake in skeletal muscle. Decrease lipolysis in adipose tissue and decrease hepatic glucose output Delay intestinal carbohydrate digestion and absorption. Inhibitors Increase urinary glucose excretion. Improve glucose-dependent insulin secretion, suppresses glucagon secretion, slow gastric emptying Prolong GLP-1 action, stimulate insulin secretion, suppress glucagon release, delay gastric emptying This article was made possible by an unrestricted educational grant from MSD, which had no control over content. Sulphonylureas & Meglitinides Insulins Increase insulin secretion from pancreatic alpha cells Increase glucose uptake in skeletal muscle and reduce hepatic glucose production Source: Cheng Y, Fantus IG. Oral anti hyperglycaemic therapy for type 2 Diabetes.CAMJ2005; 172(2): NOVEMBER
2 Timeline of treatment options Figure 1. Timeline of treatment options as they have become available to physicians among adults aged years. 4 Diabetes is also the most common single cause of end-stage renal disease. 5 The cardiovascular consequences of diabetes are devastating with 75% of diabetic patients dying from Cardiovascular events. 6 Foot ulcers and amputations are also a major cause of morbidity, disability, emotional and physical costs for people with diabetes. 7 Obesity itself is not a mild condition either, and over and above its being a risk factor for diabetes and cardiovascular disease, it also has psychosocial, pulmonary, musculoskeletal and gastrointestinal implications. Darwin would be proud. The obese society we have become has proven evolution in a rapid way. People s calorie intake has increased dramatically over the last 20 years as portion sizes have grown. This includes an increased sugar intake, much of it hidden in soft drinks and fruit juices. According to NHANES data published in Circulation in 2009, the average person over the age of one year consumes 22 teaspoons of sugar per day. 8 Dr Bayat underscored the important role lifestyle modification can play in managing diabetes. The Diabetes Prevention Program proved that its impact is sustainable over time and that regardless of age, all diabetics benefit from lifestyle measures. However, it is an ongoing challenge to persuade patients to change their eating habits and do more exercise. Treatment of diabetes Turning to pharmacological treatments for diabetes, Dr Bayat noted that where once there was only insulin and then insulin and the sulphonylureas, there is now a plethora of treatment options, all acting in different ways and at different sites in the body to address the same problem (Table 1). Earn 3 CPD points at Click on Accredited Education Programmes/CPD Practical clinical challenges However, all antidiabetic agents come with challenges that involve both physician and patient, as well as the medications themselves (Figure 2). The challenge to the physician is that he needs to optimise the use of currently available therapies to ensure adequate glycaemic, blood pressure and lipid control in Figure 2. Challenges in daily practice: interaction between physician, patient and medication 2 NOVEMBER 2014
3 Table 2. Practical hints to improve Patient Compliance with long term medication Use Combinations of: Instruction and instructional materials Simplify the regimen (e.g., less frequent dosing, controlled release dosage forms) Counsel about the regimen Support group sessions Reminders (manual and computer) for medications and appointments Cue medications to daily events Reinforcement and rewards (e.g., explicitly acknowledging the patient s efforts to adhere) Introduce Self-monitoring with regular physician review and reinforcement Involve family members and significant others Source: Based on Haynes RB, McDonald HP and Garg AX. Helping patients follow prescribed treatment: clinical applications. JAMA 2002; 288(22): order to reduce the long-term complications of type 2 diabetes. 9 The physician also needs to ensure that he prescribes a combined therapy of oral antidiabetic agents with complementary modes of action to address the underlying pathology of type 2 diabetes. This means that, aside from sulphonylureas and metformin which target fasting hyperglycaemia and have limited effect on post prandial glycaemia, he should use newer agents to control post prandial glucose excursions also. 10 Helping patients follow their prescribed therapy is a key element of the primary care practitioner s role. Some very useful practical hints have been investigated and are summarised in Table Side-effects of progressive diabetic treatment As doctors we often fail to make it clear to patients that diabetes is progressive and that they will require more drugs as time goes by. The majority of diabetic treatments cause weight gain, which creates a vicious circle, given the role of overweight and obesity in diabetes. One also needs to take into account the risk of hypoglycaemia, which is one of the reasons why relatively few patients are treated to target, despite our knowing that better HbA 1c control is associated with fewer complications and reduced risk. (Figure 3) The UKPDS early study evaluated the consequences of 6 years intensification of therapy in type 2 diabetes with sulphonylureas (mainly glibenclamide) and insulin.while it showed that glycaemic control improved, both therapies were associated with increased hypoglcaemia and weight gain. In the case of insulin, weight gain over the period was in the region of 6-10 kg and sulphonylureas usage was associated with an average of 2-4 kg of weight gain. 12 This also occurred in the more recent ADOPT trial of commonly prescribed anti-diabetic , ,2 17, ,5 5,4 5 0 n/n= 1/8 Glipizide 21/66 Glibenclamide 38/198 Gliclazide 63/351 Glimepiride 36/669 Vildagliptin Post hoc descriptive analysis. Source: Al-Arouj M, et al. The effect of vildagliptin relative to sulphonylureas in muslim patients with type 2 diabetes fasting during Ramadan. Int J Clin Pract. 2013;67(10): Figure 3. Muslim patients during Ramadan with 1 hypoglycaemic events (%) 14 NOVEMBER
4 diabetes the CV RISK equivalent agents; in this real-world study, sulphonylurea treatment was associated with an average of 1.8kg weight gain over the 4 years of the study.13 In a recent study which evaluated the effect of vildagliptin compared to Sulphonylureas in Muslim patients with type 2 Diabetes as experienced during Ramadan, the reduction in hypoglycaemic events when using vildagliptin as compared to a variety of sulphonylureas is clearly of major benefit to patients.14 Treating to target approaches International guidance for type 2 diabetes targets an HbA1c of less than 7%, but only 50% of patients reach this target. Furthermore it is of concern that some 30% have HbA1c levels above 9%. Getting to target is vital as every 1% reduction in HbA1c to a level of 7%,results in a reduced risk of deaths from diabetes (21% reduction risk), heart attacks (reduced by 14%), microvascular complications (reduced by 37%) and peripheral vascular disorders (reduced by 43%).15 Diabetes and the heart With specific reference to diabetes and the heart, Dr Bayat observed that 75% of diabetics die from a fatal cardiovascular event, but they may experience atypical presentations. Diabetes causes accelerated atherosclerosis, though we re not sure exactly why.,. Hyperglycaemia is not good for the heart, but neither is hypoglycaemia. Reducing cardiovascular risk an holistic approach It is vital to address all aspects of cardiovascular risk in type 2 diabetes; hypertension, lipids and obesity. With regard to reducing the cardio-vascular impact of hyperglycaemia, there is a huge armamentarium of glucose-lowering drugs available to the physician. Therapy comes with side-effects and it s important to first do no harm. The withdrawal of rosiglitazone further Earn 3 CPD points at Click on Accredited Education Programmes/CPD 4 NOVEMBER 2014 Figure 4. Glycemic control algorithm17 to a 2007 study that showed its association with an increased risk of myocardial infarction and death from cardiovascular causes16 led to the FDA requiring cardiovascular outcome data for all new drugs, said Dr Bayat. Consequently, we have good safety data for the incretin therapies and we do also know that metformin does not contribute to atherosclerosis or cause hypoglycaemia.
5 He therefore feels that there needs to be a patient-centric approach to treating the diabetic. In at-risk patients there should be a move away from the medication which are not as safe as they were once thought to be. But further to that, what treatments should be chosen? The ADA currently recommends metformin as preferred initial therapy if tolerated and not contraindicated. Thereafter consider insulin (with or without other agents). Alternatively add a second oral agent, GLP-1 receptor agonist or insulin. 16 The AACE glycaemic control algorithm suggests a hierarchy of usage in both monotherapy and dual therapy approaches (Figure 4). Conclusion Treatment should be individualised for each patient to ensure HbA 1c lowering with improved control, reduced hypoglycaemia, no weight gain and enhanced beta-cell function. Wrapping up, Dr Bayat underlined that diabetes is an incurable condition, often inadequately controlled and that its associated cardiovascular complications are a major concern and should always be taken into account, as not all drugs are equally safe. However, the path ahead is exciting indeed and we need to continue fixing the gaps in our current knowledge by doing trials in the best interests of our patients, he concluded. References: 1. Gray RP, Yudkin JS. Cardiovascular disease in diabetes mellitus, in Textbook of Diabetes, Eds. JC Pickup and G. Williams, 2nd edition, Blackwell Science Ltd. Oxford Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995; 122(7): Chan JM, Rimm EB, Colditz GA, et al. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 1994; 17(19): Fong DS, Aiello L, Gardner TW, King GL, Blankenship G, et al. Diabetic Retinopathy. Diabetes Care 2003; 26 (suppl 1): S99-S Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, et al. Diabetic nephropathy. Diabetes Care 2003; 26 (suppl 1): S94-S Kannel WB, D Agostino RB, Wilson PW, Belanger AJ, Gagnon DR. Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. Am Heart J 1990; 120(3): Mayfield JA, Reiber GE, Sanders LJ, Janisse D, et al. Preventive foot care in people with diabetes. Diabetes Care 2003; 26 (suppl 1) S78-S Johnson RK, Appell LJ, Brands M, American Heart Association Nutrition Committee of the Council on Nutrition, Physical Activity, and Metabolism and the Council on Epideamiology and Prevention. et al. Dietary sugars intake and cardiovascular health: a scientific statement from the American Heart Association. Circulation 2009; 120(11): Blonde L. Current challenges in diabetes management. Clin cornerstone 2005; 7 Suppl 3: S Van Gaal LF, De Leeuw IH. Rationale and options for combination therapy in the treatment of type 2 diabetes. Diabetologia 2003; 46 Suppl 1: M Haynes RB, McDonald HP and Garg AX. Helping patients follow prescribed treatment: clinical applications. JAMA 2002; 288(22): UK prospective diabetes study 16. Overview of 6 years therapy of type 2 diabetes: a progressive disease. UKPDS group. Diabetes 1995; 44(11): Viberti G, Kahn SE, Greene DA, et al. A diabetes outcome progressive trial (ADOPT): an international multicentre study of the comparative efficacy of rosiglitazone, glyburide and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002; 25(10): Al-Arouj M, Hassoun AA, Medlej R, Pathan MF, et al. The effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the VIRTUE study. Int J Clin Pract 2013; 67(10): doi: /ijcp Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321(7258): American Diabetes Association. Standards of medical care in diabetes Diabetes Care 2014; 37: Suppl Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, et al. AACE comprehensive diabetes management algorithm Endocrine Practice 2013; 19(2): CPD How to earn CPD points: Visit click on Accredited Educational Programmes/CPD, click on registration, then answer the relevant questionnaire. Your CPD certificate will be ed to you within a week. Disclaimer The views and opinions expressed in the article are those of the presenters and do not necessarily reflect those of the publisher or its sponsor. In all clinical instances, medical practitioners are referred to the product insert documentation as approved by relevant control authorities. Published by 70 Arlington Street, Everglen, Cape Town, 7550 Tel: (021) I info@denovomedica.com NOVEMBER
premix insulin and DPP-4 inhibitors what are the facts? New Sit2Mix trial provides first global evidence
Earn 3 CPD Points online Using a premix insulin (BIAsp 30) with a DPP-4 inhibitor what are the facts? New Sit2Mix trial provides first global evidence An important trial using a premix insulin (BIAsp 30)
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Dapagliflozin in combination therapy for the Final scope Remit/appraisal objective To appraise the clinical and
More informationChallenges in type 2 diabetes control: slipping control and weight gain
control Earn 3 CPD Points online Case study Challenges in type 2 diabetes control: slipping control and weight gain Presenter Dr Sedeshan Govender Specialist Physician, Endocrinologist and Diabetologists
More informationManagement of Type 2 Diabetes
Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationManagement of Type 2 Diabetes. Why Do We Bother to Achieve Good Control in DM2. Insulin Secretion. The Importance of BP and Glucose Control
Insulin Secretion Management of Type 2 Diabetes DG van Zyl Why Do We Bother to Achieve Good Control in DM2 % reduction 0-5 -10-15 -20-25 -30-35 -40 The Importance of BP and Glucose Control Effects of tight
More informationNational Horizon Scanning Centre. Saxagliptin (BMS ) for type 2 diabetes. April 2008
Saxagliptin (BMS 477118) for type 2 diabetes This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement
More information01/09/2017. Outline. SGLT 2 inhibitor? Diabetes Patients: Complex and Heterogeneous. Association between diabetes and cardiovascular events
MICROVASCULAR COMPLICATIONS Incidence of outcome g 1 Cardioprotective Effects of SGLT2s Relevant for Which T2 Diabetes Patient? SGLT 2 inhibitor? 58 year old, waist circumference 5 cm, PMH: IHD On statin,
More informationGLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
More informationIntensification after basal insulin in type 2 diabetes
Earn 3 CPD Points online Intensification after basal insulin in type 2 diabetes Introduction Professor Martin Pfohl Chief Physician Bethesda Hospital Duisburg, Germany It is vital to advise the type 2
More informationMetformin should be considered in all patients with type 2 diabetes unless contra-indicated
November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients
More informationSitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP
Sitagliptin: first DPP-4 inhibitor to treat type 2 diabetes Steve Chaplin MSc, MRPharmS and Andrew Krentz MD, FRCP KEY POINTS sitagliptin (Januvia) is a DPP-4 inhibitor that blocks the breakdown of the
More informationTREATMENTS FOR TYPE 2 DIABETES. Susan Henry Diabetes Specialist Nurse
TREATMENTS FOR TYPE 2 DIABETES Susan Henry Diabetes Specialist Nurse How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management
More informationDiabetes in the UK: Update on Diabetes Treatment and Care. Why is diabetes increasing? Obesity Increased waist circumference.
Update on Diabetes Treatment and Care Tahseen A Chowdhury Consultant Diabetologist Royal London and Mile End Hospitals Diabetes prevalence (thousands) Diabetes in the UK: 1995-21 3 25 2 15 1 5 Type 1 Type
More informationLiraglutide (Victoza) in combination with basal insulin for type 2 diabetes
Liraglutide (Victoza) in combination with basal insulin for type 2 diabetes May 2011 This technology summary is based on information available at the time of research and a limited literature search. It
More informationDiabetes Mellitus Type 2 Evidence-Based Drivers
This module is supported by an unrestricted educational grant by Aventis Pharmaceuticals Education Center. Copyright 2003 1 Diabetes Mellitus Type 2 Evidence-Based Drivers Driver One: Reducing blood glucose
More informationPatient empowerment and insulin titration
Earn 3 CPD Points online Patient empowerment and insulin titration Introduction: Empowering patients to self-titrate Dr Ted Wu Endocrinologist Australia What is patient empowerment in insulin titration
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationGLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma
More informationOptimal glucose control. DM Treatment. Glucose Control one out of many. Many guidelines: Confusing. Theorectically easy
DM Treatment How to Achieve Optimal Glycaemic Control The Tung Wah Eastern Hospital Experience of DM Share Care Experience Optimal glucose control Theorectically easy More challenging in the real world
More informationNEW SA DIABETES GUIDELINES
Earn 3 CPD Points online 2017 SEMDSA diabetes management guidelines The updated 2017 South African guidelines for the management of type 2 diabetes mellitus were launched on 5 May at the 52 nd congress
More informationHorizon Scanning Technology Summary. Liraglutide for type 2 diabetes. National Horizon Scanning Centre. April 2007
Horizon Scanning Technology Summary National Horizon Scanning Centre Liraglutide for type 2 diabetes April 2007 This technology summary is based on information available at the time of research and a limited
More informationGlucose Control drug treatments
Glucose Control drug treatments It should be noted that glitazones are under suspicion of precipitating acute cardiac events and current recommendations contraindicate the use of glitazones in patients
More informationNew Treatments for Type 2 diabetes. Nandini Seevaratnam April 2016 Rushcliffe Patient Forum
New Treatments for Type 2 diabetes Nandini Seevaratnam April 2016 Rushcliffe Patient Forum Overview Growing population of Type 2 diabetes Basic science on what goes wrong Current treatments Why there is
More informationDipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol
Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationDiabetes at the limits
Earn 3 CPD Points online Extending the limits of diabetes care Diabetes at the limits KEY MESSAGES There is a very close relationship between the extent of hypoglycaemia and the failure of glucose lowering
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationInitiating Insulin in Primary Care for Type 2 Diabetes Mellitus. Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre
Initiating Insulin in Primary Care for Type 2 Diabetes Mellitus Dr Manish Khanolkar, Diabetologist, Auckland Diabetes Centre Outline How big is the problem? Natural progression of type 2 diabetes What
More informationCombination treatment for T2DM
Combination treatment for T2DM Date of approval: December 2016 SAGLB.DIA.16.08.0657 Abbreviations ADA: American Diabetes Association CVD: Cardiovascular disease DPP-4: Dipeptidyl Peptidase-4 EASD: European
More informationUpdate on Pharmacological Management in Type 2 Diabetes
Update on Pharmacological Management in Type 2 Diabetes Prof. Lotfy Hamed Abo Dahab Professor Of Internal Medicine and Cardiology Vice President of Sohag University ١ My AGENDA Targets For Glycaemic Control
More information3. NEW DIAGNOSTIC CRITERIA, NEW CLASSIFICATION OF DM AND MODERN THERAPY APPROACH
3. NEW DIAGNOSTIC CRITERIA, NEW CLASSIFICATION OF DM AND MODERN THERAPY APPROACH 1.1 Introduction Ivana Pavlić-Renar, Ph.D. Vuk Vrhovac University Clinic, Zagreb, Croatia The current classification of
More informationClinical Overview of Combination Therapy with Sitagliptin and Metformin
Clinical Overview of Combination Therapy with Sitagliptin and Metformin 1 Contents Pathophysiology of type 2 diabetes and mechanism of action of sitagliptin Clinical data overview of sitagliptin: Monotherapy
More informationEmpagliflozin (Jardiance ) for the treatment of type 2 diabetes mellitus, the EMPA REG OUTCOME study
Empagliflozin (Jardiance ) for the treatment of type 2 diabetes mellitus, the EMPA REG OUTCOME study POSITION STATEMENT: Clinicians should continue to follow MHRA advice and NICE technology appraisal guidance
More informationFixed dose combination for Trusted Diabetes Control Lobna Farag Eltooy Head of Internal Medicine Department Assiut University
Fixed dose combination for Trusted Diabetes Control By Lobna Farag Eltooy Head of Internal Medicine Department 1 Assiut University 3/18/2018 3/18/2018 3/18/2018 Diabetes Complications with Increasing HbA1c
More informationWhy is Earlier and More Aggressive Treatment of T2 Diabetes Better?
Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:
More informationGLP-1 Receptor Agonists and SGLT-2 Inhibitors. Debbie Hicks
GLP-1 Receptor Agonists and SGLT-2 Inhibitors Debbie Hicks Prescribing and Adverse Event reporting information is available at this meeting from the AstraZeneca representative The views expressed by the
More informationYOU HAVE DIABETES. Angie O Connor Community Diabetes Nurse Specialist 25th September 2013
YOU HAVE DIABETES Angie O Connor Community Diabetes Nurse Specialist 25th September 2013 Predicated 2015 figures are already met 1 in 20 have diabetes:1in8 over 60years old Definite Diagnosis is key Early
More informationDR HJ BODANSKY MD FRCP CONSULTANT PHYSICIAN LEEDS TEACHING HOSPITALS ASSOCIATE PROFESSOR, UNIVERSITY OF LEEDS
DR HJ BODANSKY MD FRCP CONSULTANT PHYSICIAN LEEDS TEACHING HOSPITALS ASSOCIATE PROFESSOR, UNIVERSITY OF LEEDS DIABETETES UPDATE 2015 AIMS OF THE SEMINAR Diagnosis Investigation Management When to refer
More informationEarly treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationOral Agents. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
Oral Agents Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What would your ideal diabetes drug do? Effective in lowering HbA1c No hypoglycaemia No effect on weight/ weight
More informationMANAGEMENT OF TYPE 2 DIABETES
MANAGEMENT OF TYPE 2 DIABETES 3 Month trial of lifestyle changes. Refer to DESMOND structured education programme. Set glycaemic target HbA1c < 7.0% (53mmol/mol) or individualised If HbA1c > 53mmol/mol
More informationDept of Diabetes Main Desk
Dept of Diabetes Main Desk 01202 448060 Glucose management in Type 2 Diabetes in Adults The natural history of type 2 diabetes is for HbA1c to deteriorate with time. A stepwise approach to treatment is
More informationDiabetes Mellitus. Medical Management and Latest Developments Dr Ahmad Abou-Saleh
Diabetes Mellitus Medical Management and Latest Developments Dr Ahmad Abou-Saleh What is Diabetes Mellitus? A disease characterised by a state of chronic elevation of blood glucose levels due to: - The
More informationDrugs used in Diabetes. Dr Andrew Smith
Drugs used in Diabetes Dr Andrew Smith Plan Introduction Insulin Sensitising Drugs: Metformin Glitazones Insulin Secretagogues: Sulphonylureas Meglitinides Others: Acarbose Incretins Amylin Analogues Damaglifozin
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy Clinical Associate, Medical
More informationTHE FACTS ABOUT FASTING DURING RAMADAN FOR PEOPLE WITH TYPE 2 DIABETES
THE FACTS ABOUT FASTING DURING RAMADAN FOR PEOPLE WITH TYPE 2 DIABETES 1 Introduction Ramadan; one of the five pillars of Islam Fasting is an important spiritual aspect of many religions. The Islamic month
More informationNewer Drugs in the Management of Type 2 Diabetes Mellitus
Newer Drugs in the Management of Type 2 Diabetes Mellitus Dr. C. Dinesh M. Naidu Professor of Pharmacology, Kamineni Institute of Medical Sciences, Narketpally. 1 Presentation Outline Introduction Pathogenesis
More informationType 2 DM in Adolescents: Use of GLP-1 RA. Objectives. Scope of Problem: Obesity. Background. Pathophysiology of T2DM
Type 2 DM in Adolescents: Use of GLP-1 RA Objectives Identify patients in the pediatric population with T2DM that would potentially benefit from the use of GLP-1 RA Discuss changes in glycemic outcomes
More informationDiabesity. Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs
Diabesity Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs Abdominal obesity Low HDL, high LDL, and high triglycerides HTN High blood glucose (F>100l,
More informationSIGN 154 Pharmacological management of glycaemic control in people with type 2 diabetes. A national clinical guideline November 2017.
SIGN 154 Pharmacological management of glycaemic control in people with type 2 diabetes A national clinical guideline November 2017 Evidence KEY TO EVIDENCE STATEMENTS AND RECOMMENDATIONS LEVELS OF EVIDENCE
More informationSoliqua (insulin glargine and lixisenatide), Xultophy (insulin degludec and liraglutide)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.48 Subject: Insulin GLP-1 Combinations Page: 1 of 5 Last Review Date: September 15, 2017 Insulin GLP-1
More informationWHO Guidelines for Management of Diabetes in Low Resource Settings
WHO Guidelines for Management of Diabetes in Low Resource Settings 24 th November, 2018 Dr. Alok Shetty K Senior Resident Department of Medicine St. John s Medical College & Hospital WHO vs ADA-EASD Revisiting
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationTRANSPARENCY COMMITTEE OPINION. 15 October 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 October 2008 TANDEMACT 30 mg/20 mg tablets Box of 30 (CIP: 386 566-3) Box of 90 (CIP: 386 568-6) TANDEMACT 30 mg/4
More informationSodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol
Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has
More informationPharmacological Glycaemic Control in Type 2 Diabetes
Pharmacological Glycaemic Control in Type 2 Diabetes Aim(s) and Objective(s) This guideline aims to offer advice on the pharmacological management for those who require measures beyond diet and exercise
More informationSitagliptin. Agreed by Clinical Priorities Group
New Medicine Report Document Status Sitagliptin Agreed by Clinical Priorities Group Traffic Light Decision Blue- Primary Care Prescriber s Rating Offers an advantage - The product has some value but does
More informationAbbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone
Index Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone Medication GAD glutamic acid decarboxylase GLP-1 glucagon-like peptide 1 NPH neutral
More informationHow can we improve outcomes in Type 2 diabetes?
How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management Identify and treat all risk factors Use rational pharmacological therapy
More informationT2DM is a global epidemic with
: a new option for the management of type 2 diabetes Marc Evans MRCP, MD, Consultant Diabetologist, Llandough Hospital, Cardiff Incretin-based therapies for the treatment of diabetes mellitus (T2DM) present
More informationTRANSPARENCY COMMITTEE OPINION. 29 April 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 April 2009 VELMETIA 50 mg/850 mg, film-coated tablets B/56 (CIP code: 386 778-0) VELMETIA 50 mg/1 000 mg, film-coated
More informationSGLT2 Inhibitors
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: SGLT2 Inhibitors Page: 1 of 7 Last Review Date: November 30, 2018 SGLT2 Inhibitors Description
More informationLearning Objectives. Impact of Diabetes II UPDATES IN TYPE 2 DIABETES. David Doriguzzi, PA-C
UPDATES IN TYPE 2 DIABETES David Doriguzzi, PA-C Learning Objectives Upon completion of this educational activity, the participant should be able to: Overcome barriers and attitudes that limit Clinician/Patient
More informationCurrent Diabetes Care for Internists:2011
Current Diabetes Care for Internists:2011 Petch Rawdaree, DM, MSc, DLSHTM Faculty of Medicine Vajira Hospital University of Bangkok Metropolis 19 th January 2011 ก ก 1. ก ก ก ก 2. ก ก ก ก ก 3. ก ก ก ก
More informationAlia Gilani Health Inequalities Pharmacist
Alia Gilani Health Inequalities Pharmacist THE SOUTH ASIAN HEALTH FOUNDATION (U.K.) (Registered Charity No. 1073178) 1. Case Study 2. Factors influencing prescribing 3. Special Considerations 4. Prescribing
More informationHypertension is the most important cause of death globally, while the
CARDIOMETABOLIC DISEASE Earn 3 CPD Points online This article was made possible by an unrestricted educational grant by Servier Laboratories. New approaches to cardiometabolic disease Hypertension is the
More informationDIA LEAGUE DIA LEAGUE. 06 th November, Chandigarh, India
06 th November, Chandigarh, India : "The Dia League CME was held at Chandigarh under the banner of Asian Society of Continuing Medical Education. The CME was designed to get all the Diabetologist, Endocrinologist
More informationOral Pharmacologic Treatment of Type 2 Diabetes Mellitus
Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus You should be offering psychosocial care to all patients with diabetes, says the ADA. Here are the specific recommendations. Summary Recommendation
More informationAchieving Excellence in Diabetes. The Importance of Incremental Care
Achieving Excellence in Diabetes The Importance of Incremental Care Kieran Walshe MD MRCGP FRCPE GP and Diabetes Specialist Diabetes in Ireland 2015: Estimated prevalence of diabetes 5.5% Estimated prevalence
More informationDiabetes: Staying Two Steps Ahead. The prevalence of diabetes is increasing. What causes Type 2 diabetes?
Focus on CME at the University of University Manitoba of Manitoba : Staying Two Steps Ahead By Shagufta Khan, MD; and Liam J. Murphy, MD The prevalence of diabetes is increasing worldwide and will double
More informationMOA: Long acting glucagon-like peptide 1 receptor agonist
Alexandria Rydz MOA: Long acting glucagon-like peptide 1 receptor agonist Increases glucose dependent insulin secretion Decreases inappropriate glucagon secretion Increases β- cell growth and replication
More informationCase study: Lean adult with no complications, newly diagnosed with type 2 diabetes
Case study: Lean adult with no complications, newly diagnosed with type 2 diabetes Authored by Clifford Bailey and James LaSalle on behalf of the Global Partnership for Effective Diabetes Management. The
More informationPre-diabetes. Pharmacological Approaches to Delay Progression to Diabetes
Pre-diabetes Pharmacological Approaches to Delay Progression to Diabetes Overview Definition of Pre-diabetes Risk Factors for Pre-diabetes Clinical practice guidelines for diabetes Management, including
More informationSIMPLICITY IN T2DM MANAGEMENT WITH DPP4 INHIBITORS: SPECIAL POPULATION
SIMPLICITY IN T2DM MANAGEMENT WITH DPP4 INHIBITORS: SPECIAL POPULATION DR ROSE ZHAO-WEI TING ( 丁昭慧醫生 ) MBBS (HK), MRCP (UK), FHKCP, FHKAM (MEDICINE) Specialist in Endocrinology, Diabetes and Metabolism
More informationShould Psychiatrists be diagnosing (and treating) metabolic syndrome
Should Psychiatrists be diagnosing (and treating) metabolic syndrome David Hopkins Clinical Director, Diabetes King s College Hospital, London Diabetes prevalence (thousands) Diabetes in the UK: 1995-2010
More informationMr Rab Burtun. Dr David Kim. 8:30-10:30 WS #2: Diabetes Basic 11:00-13:00 WS #9: Diabetes Basic (Repeated)
Dr David Kim Endocrinologist and General Physician Waitemata DHB and Apollo Specialist Clinic Albany Auckland Mr Rab Burtun Diabetes Nurse Specialist Waitemata DHB Waitakere Hospital Auckland 8:30-10:30
More informationDiabetes Mellitus Aeromedical Considerations. Aviation Medicine Seminar Bucharest, Romania. 11 th to 15 th November 2013
Diabetes Mellitus Aeromedical Considerations Aviation Medicine Seminar Bucharest, Romania. 11 th to 15 th November 2013 Metabolic, Nutritional or Endocrine disorders Applicants with metabolic, nutritional
More informationHow to organize good diabetes care team. Sunitaya Chandraprasert, MD.
How to organize good diabetes care team Sunitaya Chandraprasert, MD. Scope Overview of DM Multidisplinary team What is diabetes Metabolic disorder of multiple etiology Chronic hyperglycemia result from
More informationSitagliptin: A component of incretin based therapy. Rezvan Salehidoost, M.D., Endocrinologist
Sitagliptin: A component of incretin based therapy Rezvan Salehidoost, M.D., Endocrinologist Agenda Mode of Action Evidences for sitagliptine cardiovascular safety of sitagliptin Ramadan study Impact of
More informationWayne Gravois, MD August 6, 2017
Wayne Gravois, MD August 6, 2017 Americans with Diabetes (Millions) 40 30 Source: National Diabetes Statistics Report, 2011, 2017 Millions 20 10 0 1980 2009 2015 2007 - $174 Billion 2015 - $245 Billion
More informationIDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and Diabetes Atlas -sixth Edition: IDF 2013
IDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and 2035 Diabetes Atlas -sixth Edition: IDF 2013 Diabetes Atlas -sixth Edition: IDF 2013 Chronic complications
More informationDiabetes Mellitus: Implications of New Clinical Trials and New Medications
Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October
More informationDiabetes treatment by the algorithm
Diabetes treatment by the algorithm Joseph Dawley, M.D. Southwest Oklahoma Family Medicine Residency Oklahoma University Health Sciences Center Clinical Assistant Professor Objectives By the end of this
More informationScottish Medicines Consortium
Scottish Medicines Consortium liraglutide 6mg/mL prefilled pen for injection (3mL) (Victoza ) Novo Nordisk Ltd. No. (585/09) 06 November 2009 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationGuidelines to assist General Practitioners in the Management of Type 2 Diabetes. April 2010
Guidelines to assist General Practitioners in the Management of Type 2 Diabetes April 2010 Foreword The guidelines were devised by the Diabetes Day Centre in Beaumont Hospital in consultation with a number
More informationNavigating the New Options for the Management of Type 2 Diabetes
Navigating the New Options for the Management of Type 2 Diabetes Clinical Associate Professor Mark Kennedy Department of General Practice, University of Melbourne Chair, Primary Care Diabetes Society of
More informationSulfoniluree e glinidi: pro e contro
Sulfoniluree e glinidi: pro e contro Giorgio Sesti Università Magna Graecia di Catanzaro ITALY T2DM anti-hyperglycaemic therapy: general recommendations Diabetes Care 35:1364-1379, 2012; Diabetologia 55:1577-1596,
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationDIABETES AND RAMADAN FASTING
DIABETES AND RAMADAN FASTING Dr. A. Nigam, M.B.B.S., M.D. (Medicine) Specialist Internal Medicine Al Zahrawi Hospital, Ras Al Khaimah, U.A.E. It is estimated that UAE s population currently stands at approximately
More informationBristol-Myers Squibb / AstraZeneca ADVICE dapagliflozin (Forxiga ) Indication under review: SMC restriction: Chairman, Scottish Medicines Consortium
Re-Submission dapagliflozin 5mg and 10mg film-coated tablets (Forxiga ) SMC No. (799/12) Bristol-Myers Squibb / AstraZeneca 07 February 2014 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationDiabetes mellitus. Treatment
Diabetes mellitus Treatment Recommended glycemic targets for the clinical management of diabetes(ada) Fasting glycemia: 80-110 mg/dl Postprandial : 100-145 mg/dl HbA1c: < 6,5 % Total cholesterol: < 200
More informationData from an epidemiologic analysis of
CLINICAL TRIAL RESULTS OF GLP-1 RELATED AGENTS: THE EARLY EVIDENCE Lawrence Blonde, MD, FACP, FACE ABSTRACT Although it is well known that lowering A 1c (also known as glycated hemoglobin) is associated
More informationDrug Class Review Newer Diabetes Medications and Combinations
Drug Class Review Newer Diabetes Medications and Combinations Final Update 2 Report July 2016 The purpose reports is to make available information regarding the comparative clinical effectiveness and harms
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationNormal Fuel Metabolism Five phases of fuel homeostasis have been described A. Phase I is the fed state (0 to 3.9 hours after meal/food consumption),
Normal Fuel Metabolism Five phases of fuel homeostasis have been described A. Phase I is the fed state (0 to 3.9 hours after meal/food consumption), in which blood glucose predominantly originates from
More informationPractical clinical guide: adding GLP-1 RAs to intensify type 2 diabetes therapy
EARN 3 FREE CD OINTS diabetes Leader in digital CD for Southern African healthcare professionals ractical clinical guide: adding GL-1 RAs to intensify type 2 diabetes therapy atient selection guided by
More informationThis program applies to Commercial, GenPlus and Health Insurance Marketplace formularies.
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) Agonists [Adlyxin (lixisenatide), Byetta (exenatide), Bydureon (exenatide extended-release), Tanzeum (albiglutide), Trulicity (dulaglutide),
More informationAmbulatory blood pressure monitoring is key to improving hypertension diagnosis
Earn 2 CEU Points online Ambulatory blood pressure monitoring is key to improving hypertension diagnosis Professor Bryan Williams Director of the UCL Biomedical Research Centre University College London
More informationDrug Class Monograph
Drug Class Monograph Class: Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drugs: alogliptin, alogliptin/metformin, Januvia (sitagliptin), Janumet (sitagliptin/metformin), Janumet XR (sitagliptin/metformin),
More information